一期与二期肱动脉-贵要静脉动静脉瘘创建的的系统综述与荟萃分析
该系统综述与荟萃分析比较一期与二期肱动脉-贵要静脉动静脉瘘创建的疗效,纳入2项随机对照试验和9项病例队列研究。两组失败率、1年原发通畅率、1年及2年继发通畅率无统计学显著差异,但二期组2年原发通畅率显著改善(RR 2.50,95%CI 1.66-3.74,P<.00001)。作者认为二期可能有益,但强调仍需设计良好的随机对照试验进一步验证。
要点
- 两组失败率、1年原发通畅率、1年及2年继发通畅率无统计学显著差异。
- 二期组2年原发通畅率显著优于一期组(RR 2.50,95%CI 1.66-3.74,P<.00001)。
- 并发症无显著差异,一期组术后血栓形成有增加趋势(RR 1.81,95%CI 0.95-3.45,P=.07)。
核心结论
- 二期肱动脉-贵要静脉动静脉瘘创建2年原发通畅率改善且并发症无显著差异,作者认为二期相较一期可能有潜在获益。
- 作者指出该结果并非定论,仅强调仍需足够把握度、设计良好的随机对照试验进一步探究该问题。
研究设计与样本
- 系统综述与荟萃分析,按PRISMA指南实施,检索MEDLINE、EMBASE、Google Scholar和Cochrane Database。
- 系统检索共发现242篇可能纳入的文献,经标题和摘要筛选后纳入2项随机对照试验和9项病例队列研究。
- 偏倚风险和质量评价评分均基于既往验证的工具进行。
主要发现
- 两组失败率无统计学显著差异(合并风险比RR 1.10,95%CI 0.79-1.55,P=.25)。
- 两组1年原发通畅率无统计学显著差异(RR 1.31,95%CI 0.83-2.06,P=.24)。
- 两组1年继发通畅率无统计学显著差异(RR 0.97,95%CI 0.54-1.77),2年继发通畅率无统计学显著差异(RR 1.19,95%CI 0.54-2.63,P=.67)。
- 二期组2年原发通畅率显著优于一期组(RR 2.50,95%CI 1.66-3.74,P<.00001)。
- 窃血综合征、血肿、感染、假性动脉瘤或狭窄无差异,但一期组术后血栓形成有增加趋势(RR 1.81,95%CI 0.95-3.45,P=.07)。
局限性
- 作者指出该结果并非定论,仅强调仍需足够把握度、设计良好的随机对照试验进一步探究该问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term patency of arteriovenous fistulas (AVFs) is critical for hemodialysis vascular access. We compared the efficacy of a one-stage vs two-stage approach to brachiobasilic AVF creation by primarily investigating primary and secondary patency rates. We hypothesize that the two-stage is superior to the one-stage procedure in terms of efficacy and safety. METHODS: This review was performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Searches were performed on MEDLINE, EMBASE, Google Scholar, and Cochrane Database. Risk of bias and quality assessment scores were both performed based on previously validated tool. RESULTS: The systematic search revealed a total of 242 publications for possible inclusion. On the basis of title and abstract review, two randomized controlled trials and nine case-cohort series fit our inclusion criteria. There were no statistically significant differences in failure rates (pooled risk ratio [RR], 1.10; 95% confidence interval [CI], 0.79-1.55; P = .25), 1-year primary patency rates (RR, 1.31; 95% CI, 0.83-2.06; P = .24), 1-year secondary patency rates (RR, 0.97; 95% CI, 0.54-1.77) and 2-year secondary patency rates (RR, 1.19; 95% CI, 0.54-2.63; P = .67) between both groups. However, the two-stage procedure had significantly improved 2-year primary patency rates (RR, 2.50; 95% CI, 1.66-3.74; P < .00001). There were no differences in steal syndrome, hematoma, infection, pseudoaneuryms, or stenosis, although there was a trend toward an increased incidence of postoperative thrombosis (RR, 1.81; 95% CI, 0.95-3.45; P = .07) in one-stage procedures. CONCLUSIONS: With improved 2-year primary patency rates and the absence of significant differences in complications, this study suggests potential benefit of a two-stage over a one-stage procedure for brachiobasilic AVF creation. However, rather than being a definitive answer, our results merely highlight the continuing need for an adequately powered, well-designed, randomized controlled trial to interrogate this question further.
引用
- Jun Yan Wee I, Mohamed IH, Patel A, et al. A systematic review and meta-analysis of one-stage versus two-stage brachiobasilic arteriovenous fistula creation. J Vasc Surg. 2018. PMID: 29937034. doi:10.1016/j.jvs.2018.03.428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。